GV-17(GV-17) - 在研适应症：系统性红斑狼疮_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

系统性红斑狼疮

非在研适应症-

原研机构

健亞生物科技股份有限公司

在研机构

健亞生物科技股份有限公司

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 GV-17 相关的临床结果

登录后查看更多信息

100 项与 GV-17 相关的转化医学

登录后查看更多信息

100 项与 GV-17 相关的专利（医药）

登录后查看更多信息

1

项与 GV-17 相关的文献（医药）

Foods

Technological Assessment and Predictive Modeling of Probiotic Lactose-Free Fermented Milk with Lacticaseibacillus paracasei GV17

Article

作者: Salotti-Souza, Bruna Maria ; Rossi, Gabriel Augusto Marques ; Fante, Camila Argenta ; Costa, Isabella Maciel ; de Souza, Marcelo Resende ; Costa, Taynan Jonatha Neves ; Magalhães, Larissa Mirelle Mendes

This study investigated Lacticaseibacillus paracasei GV17, a potentially probiotic strain, in association with the commercial culture Streptococcus thermophilus STI-12, in lactose-free fermented milk. Predictive modeling was used to estimate growth parameters and microbial viability and the technological characteristics of the fermented milk during storage. The initial concentrations of the strains were 9.80 log CFU/mL for Lc. paracasei GV17 and 9.50 log CFU/mL for S. thermophilus STI-12. After eight hours, the pH reached 4.6, and the concentrations of GV17 and STI-12 were 10.90 log CFU/mL and 11.20 log CFU/mL, respectively. The Baranyi model was fitted to the growth data, with correlation coefficients of 0.760 for Lc. paracasei GV17 and 0.852 for St. thermophilus STI-12. The maximum specific growth rates were 0.912 log CFU/h for GV17 and 0.882 log CFU/h for STI-12. Regarding technological characteristics, syneresis decreased by 8.90% after 28 days, indicating greater structural stability, while water retention capacity remained constant. The viability of LAB remained above 10.00 log CFU/mL. Lc. paracasei GV17 showed great potential for use in functional products, prompting further research.

100 项与 GV-17 相关的药物交易

登录后查看更多信息